



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy
18-20 September 2025

Thursday, 18 September 2025

10:00 – 12:00

Scientific Business Meetings

13:00 – 13:55

Session I: Current EBMT recommendations

Chairs: Tobias Alexander (DE) & Donal McLornan (UK)

13:00 – 13:15

EBMT recommendations for HCT in MDS

Carmelo Gurnari (IT)

13:15 – 13:30

EBMT recommendations for HCT in autoimmune diseases

Elisa Roldan Galvan (UK)

13:30 – 13:45

EBMT recommendations for CART in autoimmune diseases

Raffaella Greco (IT)

13:45 – 13:55

Panel discussion

13:55 – 15:00

Session II: MDS diagnosis and prognosis

Chairs: Kavita Raj (UK) & Adriano Venditti (IT)

13:55 – 14:10

MDS in 2025: a molecular era of diagnostic and prognostic classifiers

Mario Cazzola (IT)

14:10 – 14:25

HCT or not in MDS? How to decide with current prognostic scoring systems

Nico Gagelmann (DE)

14:25 – 14:40

Are we ready for AI to help in the management of MDS?

Adrian Mosquera (ES)

14:40 – 15:00

Panel discussion

15:00 – 15:30

Coffee break

15:30 – 16:50

Session III: MDS treatment

Chairs: Fernando Barroso Duarte (BR) & Nicolaus Kröger (DE)

15:30 – 15:45

Current treatment algorithm in Lower-risk MDS

Maria Teresa Voso (IT)

15:45 – 16:00

Current treatment algorithm in Higher-risk MDS and the AML/MDS border

Amer Zeidan (US)

16:00 – 16:15

Therapeutic vulnerability in MDS/AML: looking into the future from the lab standpoint

Jaroslav Maciejewski (US)

16:15 – 16:30

Access to genomics and transplant policies in MDS in Latin-America

Gonzalo Bentolila (AR)

16:30 – 16:40

Case presentation

Giuliano Filippini Velazquez (DE)

16:40 – 16:50

Panel discussion

16:50 – 17:20

Coffee break

17:20 – 18:25

Session IV: Autoinflammation in haematology and beyond

Chairs: Joanna Drozd-Sokolowska (PL) & Anna Paola Iori (IT)

17:20 – 17:35

VEXAS: the lynchpin between inflammation and myeloid neoplasia

Carmelo Gurnari (IT)

17:35 – 17:50

CMML and autoimmune/inflammatory conditions

Francesco Onida (IT)

17:50 – 18:05

Incidence and management of HLH in autoimmune diseases

Coralie Bloch (FR)

18:05 – 18:15

Case presentation

18:15 – 18:25

Case presentation

Syed Ali (AU)



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy
18-20 September 2025

Friday, 19 September 2025

09:00 – 10:10 Joint Physician-Nurse session HCT in MDS in 2025

Chairs: *Maike de Ruijter (NL) & William Arcese (IT)*

09:00 – 09:15	Which donor to choose in the PtCy era?
09:15 – 09:30	Bridging or not prior to allo-HCT for MDS?
09:30 – 09:45	Conditioning regimens in the contemporary era
09:45 – 10:00	Issues on maintenance and management of relapse
10:00 – 10:15	Panel discussion

Kavita Raj (UK)
Nicolaus Kröger (DE)
Joanna Drozd-Sokolowska (PL)
Marie Robin (FR)

10:15 – 11:00 Industry Symposium

11:00 – 11:30 Coffee break

11:30 – 12:50 Session V: HCT in autoinflammation and autoimmunity

Chairs: *John Snowden (UK) & Andrea Bacigalupo (IT)*

11:30 – 11:45	HCT in VEXAS
11:45 – 12:00	HCT in Behçet's disease
12:00 – 12:15	HCT in systemic sclerosis
12:15 – 12:30	HCT for AID in Brazil: Current Practices
12:30 – 12:40	Case presentation

Donal McLornan (UK)
Mathieu Puyade (FR)
Nicoletta del Papa (IT)
Fernando Barroso Duarte (BR)
Gavin Brittain (UK)

12:40 – 12:50 Panel discussion

12:50 – 14:00 Lunch break

14:00 – 15:20 Session VI: Plasma cells as treatment targets in haematology and autoimmune diseases

Chairs: *Patrizia Chiusolo (IT) & Paolo Muraro (UK)*

14:00 – 14:15	Novel treatment approaches in myeloma
14:15 – 14:30	Bispecifics in myeloma: bridging to CAR-T?
14:30 – 14:45	Bone marrow plasma cell landscape in health and disease
14:45 – 15:00	Plasma cell depletion in autoimmune diseases
15:00 – 15:10	Case presentation
15:10 – 15:20	Case presentation

Elisa Roldan Galvan (UK)
Patrick Hayden (IE)
Farzin Mashreghi (DE)
Tobias Alexander (DE)

Jonathan Wickel (DE)

15:20 – 15:50 Coffee break

15:50 – 17:15 Session VII: Novel cellular therapies in autoimmune diseases

Chairs: *Simona Sica (IT) & Dominique Farge (FR)*

15:50 – 16:05	Bispecific antibodies in rheumatoid arthritis
16:05 – 16:20	CART in rheumatoid arthritis
16:20 – 16:35	CAR-T cell therapies in pediatric autoimmune diseases
16:35 – 16:50	iPS cells for tissue regeneration in autoimmune disease
16:50 – 17:00	Case presentation
17:00 – 17:15	Panel discussion

Ricardo Grieshaber (DE)
Doron Rimar (IS)
Marco Becilli (IT)
Richard Burt (US)
Ioanna Minopoulou (DE)



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy
18-20 September 2025

Saturday, 20 September 2025

08:45 – 09:45 Joint Nurse-Physician session HSCT and cellular therapies for autoimmune neurologic diseases

Chairs: *Claudia Boglione (IT) & Basil Sharrack (UK)*

08:45 – 09:00 Autologous HCT in MS

09:00 – 09:15 CAR T in MS

09:15 – 09:30 Cellular therapies in other neurologic indications

09:30 – 09:45 Panel discussion

Alice Mariottini (IT)

Lena Kristina Pfeffer (DE)

Aiden Haghikia (DE)

10:00 – 10:45 Industry Symposium

10:45 – 11:30 Poster Tour

11:30 – 12:45 Session VIII: Immune monitoring post CART and late complications for autoimmune disease

Chairs: *Franco Locatelli (IT) & Raffaella Greco (IT)*

11:30 – 11:45 Immune monitoring post-CART

11:45 – 12:00 Late complications in HCT

12:00 – 12:15 Late complications in CART

12:15 – 12:30 Secondary HLH after CART

12:30 – 12:45 Panel discussion

Simona Pagliuca (FR)

Kirill Krigizov (RU)

Maeve O'Reilly (UK)

Matteo Doglio (IT)

12:45 – 13:00 Take-home messages from all the organizers